RGNX vs. IMCR, SDGR, EWTX, BHVN, ETNB, ANIP, VERA, JANX, EVO, and OCUL
Should you be buying REGENXBIO stock or one of its competitors? The main competitors of REGENXBIO include Immunocore (IMCR), Schrodinger (SDGR), Edgewise Therapeutics (EWTX), Biohaven (BHVN), 89BIO (ETNB), ANI Pharmaceuticals (ANIP), Vera Therapeutics (VERA), Janux Therapeutics (JANX), Evotec (EVO), and Ocular Therapeutix (OCUL). These companies are all part of the "pharmaceutical products" industry.
REGENXBIO vs. Its Competitors
Immunocore (NASDAQ:IMCR) and REGENXBIO (NASDAQ:RGNX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.
In the previous week, Immunocore had 6 more articles in the media than REGENXBIO. MarketBeat recorded 8 mentions for Immunocore and 2 mentions for REGENXBIO. REGENXBIO's average media sentiment score of 1.24 beat Immunocore's score of 0.46 indicating that REGENXBIO is being referred to more favorably in the news media.
Immunocore currently has a consensus target price of $58.89, indicating a potential upside of 87.66%. REGENXBIO has a consensus target price of $31.63, indicating a potential upside of 285.20%. Given REGENXBIO's stronger consensus rating and higher possible upside, analysts plainly believe REGENXBIO is more favorable than Immunocore.
Immunocore has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, REGENXBIO has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500.
Immunocore has a net margin of -6.48% compared to REGENXBIO's net margin of -100.62%. Immunocore's return on equity of -5.86% beat REGENXBIO's return on equity.
Immunocore has higher revenue and earnings than REGENXBIO. Immunocore is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.
84.5% of Immunocore shares are held by institutional investors. Comparatively, 88.1% of REGENXBIO shares are held by institutional investors. 10.4% of Immunocore shares are held by insiders. Comparatively, 12.8% of REGENXBIO shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Immunocore beats REGENXBIO on 9 of the 16 factors compared between the two stocks.
Get REGENXBIO News Delivered to You Automatically
Sign up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
REGENXBIO Competitors List
Related Companies and Tools
This page (NASDAQ:RGNX) was last updated on 7/1/2025 by MarketBeat.com Staff
